{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076624","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-06-23T11:00:41+00:00","discovered_at":"2026-06-23T11:05:00.247242+00:00","generated_at":"2026-06-23T11:05:22.601882+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nuvectis in-licenses ex-China rights to two clinical-stage compounds from Haisco for up to $1.46B","bullets":["Upfront and near-term payments total up to $40M; potential milestones up to $1.421B plus tiered royalties.","NXP100 (CFBi) has two MAAs under review in China for PNH; Ph3 ongoing in IgAN; Ph2 in LN.","NXP200 (paradox-breaker BRAFi) showed >40% response in gliomas and durable responses in multiple tumors; Phase 1b ongoing.","Deal transforms Nuvectis into late-stage clinical company with two best-in-class potential assets.","Agreement subject to financing conditions to ensure sufficient capital for product development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076624","json":"https://secwatch.observer/filing/0001104659-26-076624.json","markdown":"https://secwatch.observer/filing/0001104659-26-076624.md","text":"https://secwatch.observer/filing/0001104659-26-076624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/0001104659-26-076624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:05:22.601882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}